BioSpace News Archive

Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 -positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the Company will participate in two investor conferences in September.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 7:30 a.m. EST.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer.

Omega Therapeutics, Inc. announced that Chris Schade has been appointed as Chairman of the Board, succeeding Noubar Afeyan, Ph.D. In addition, Michelle C. Werner will join Omega’s Board to support the Company’s growth.

Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), positioning Apellis for long-term success.

Societal CDMO, Inc. announced that the company closed its previously announced underwritten public offering of 20,750,000 shares of its common stock at a public offering price of $0.40 per share of common stock on Monday, August 28, 2023.

Clene Inc. through its wholly owned subsidiary Clene Nanomedicine Inc., announced the 24-month long-term data cut from the Phase 2 RESCUE-ALS ongoing open-label extension as of July 2023, which showed a significant median survival benefit of 19.3 months using the rank-preserving structural failure time model and a significant 52% decreased risk of ALS clinical worsening events with CNM-Au8® treatment.